alexa Use of Informatics in Identification of Adverse Drug Reactions | Open Access Journals
ISSN: 0975-0851
Journal of Bioequivalence & Bioavailability
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Use of Informatics in Identification of Adverse Drug Reactions

Sachin Devi*
Director, Laboratory of Experimental & Clinical Toxicology, LECOM-School of Pharmacy, Bradenton, FL, 34203, USA
Corresponding Author : Sachin Devi
Director, Laboratory of Experimental & Clinical Toxicology
LECOM-School of Pharmacy
Bradenton, FL, 34203, USA
Tel: 941-782-5941
Received July 18, 2014; Accepted July 21, 2014; Published July 28, 2014
Citation: Devi S (2014) Use of Informatics in Identification of Adverse Drug Reactions. J Bioequiv Availab 6:e54. doi: 10.4172/jbb.10000e54
Copyright: © 2014 Devi S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Bioequivalence & Bioavailability

What are Adverse Drug Reactions?
Adverse drug reactions (ADRs) can be defined as, “Any response to a drug that is noxious and unintended, and that occurs at doses used in humans for prophylaxis, diagnosis, or therapy, excluding failure to accomplish the intended purpose.” [1].
ADRs are commonly divided into two subtypes: 1) Type A and 2) Type B.
Type A ADRs are usually manifestations of exaggerated response of the known effect of the drug (e.g. bleeding from warfarin treatment). They are common and majority of them are attributed to pharmacokinetic or pharmacodynamic interactions. Most of these ADRs are predictable and therefore, preventable. On the other hand, type B ADRs are less common, serious and unpredictable. Majority of these types of ADRs are mediated by immune system and also termed as “hypersensitivity reactions”.
Meta-analysis of prospective studies estimated that 6.7% of hospitalized patients have serious ADRs [2]. If these estimates are correct then ADRs are leading cause of death. It should be noted that these estimate do not include ADRs that occur in ambulatory setting. Even though there is no method that accurately measures the estimates of ADRs, there is general consensus that ADRs pose greater risk to public health. It should be emphasized that most of these ADRs are preventable.
Why there are so many Incidences of Adrs and What is being done about them?
These high incidences of ADRs raise logical question:why do so many ADRs occur in spite of thorough preclinical and clinical studies? There are several possible reasons. Here are few: 1) The number of physician visits has gone up 2) thenumbers of prescriptions have gone up 3) several patients take multiple medications. It has been demonstrated that the rate of ADRs increases exponentially after a patient is on 4 or more medications [3].
The next logical question is why ADRs are not identified before drugs are marketed to mass population? During preclinical trials, safety pharmacologists and toxicologists conduct several studies in order to identify potential ADRs including drug-drug interactions [4]. However, many of these studies are focused on major organ system and have limited impact to predict ADRs due to genetic or demographic variations. Additionally, there are millions of possible combinations of drugs given to the patients. Studying all of the drug-drug interactions during preclinical trials is not practical. Clinical trials are usually conducted on few hundred patients [5]. Therefore, rare ADRs (for example, 1 in 100,000 patient exposures) cannot be identified during clinical trials. These ADRs are generally identified only after millions of patients are exposed after marketing of these drugs to mass population. This underscores the importance and need for post-marketing surveillance.
Several measures have been implemented to identify and prevent ADRs after the drug has reached to the market. First and foremost is “Medwatch” program created by Food & Drug Administration (FDA). This is online ADR reporting system that encourages healthcare professionals to report suspicious serious ADR regardless of the causality. Additionally, many health systems have implemented electronic health records. There are several software programs available that assist healthcare professionals to prescribe and store patients’ medical records. New generation computer software programs are able to detect and alert healthcare professional when combination of drugs with potential to cause ADRs are prescribed. It has been shows that optimal drug dosage with the help of computerized advice has beneficial effects on patient outcomescompared with empiric dosing without computer assistance) [6]. For example, managing therapeutics concentration of the drugs with narrow therapeutics window is challenging task. There are many software systems that have been designed to assist physicians to determine optimum drug dosage.
Role of Informatics in Identifying and Preventing ADRs
Large scale data collection hasgenerated vast amount of information. For example, healthcare professionals are encouraged to report possible ADR even if it is based on suspicion. This has created lot of noise and sifting through these datasets for the detection of possible ADR signal remains a challenge. Informatics thrives on these kinds of large datasets. Logical assumptions and hypotheses can assist in writing algorithms to develop software programs that can fade background noise and detect potential ADR signals.
Most of the software programs that are used as a part of electronic medical records systems are designed to generate alert in order to prevent errors. However, several studies indicated that frequent drug alerts result in “alert-fatigue” and can lead to overall ignorance of such alerts by healthcare professionals. Further research is needed to grade ADRs based on risk potential and to develop informatics programs that can generate only “high-value alerts”. Additionally, several studies suggested that even though information is available, it is not optimally incorporated in decision-making process. Therefore, highly sophisticated informatics programs with better user interface must be designed to assist healthcare professional to sift through the plethora of information and utilize it in routine decision making process.
Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11533
  • [From(publication date):
    July-2014 - Jun 27, 2017]
  • Breakdown by view type
  • HTML page views : 7791
  • PDF downloads :3742

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

1-702-714-7001Extn: 9037

Business & Management Journals


1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version